Factoring in a more moderate earnings recovery; long-term view intact
11/04/24 -"The 2023 bottom line was materially below our expectations owing to the slower-than-expected recovery in profitability and higher interest expenses. Taking our cue from the 2023 trend, we have ..."
Pages
53
Language
English
Published on
11/04/24
You may also be interested by these reports :
23/06/26
Our estimates for 2026 and 2027 are significantly affected by net financial expenses. The firm raised $5.5bn to fund the Merus acquisition, which is ...
19/06/26
Evaluating Pharma’s Defences
17/06/26
Our target price is reduced to CHF94 (from CHF97) on the back of a lower sales base. We have also adjusted forward years’ growth, slightly increasing ...
15/06/26
The target price is upgraded on the back of higher margins in 2026. The EBITDA margin is lifted from 15.4% to 17.9% for the full year (guidance is ...